Growth Capitalist (https://growthcapitalist.com/author/moriarty/page/156/)
Transgenomic, Inc. (TBIO) announced that it has raised $6,999,990 in a Convertible Preferred Stock transaction. The fixed conversion price of the Convertible Preferred Stock is $4.85 per share, an approximate 1.04% premium to the market price ($4.80) of TBIO at deal announcement. The investor was Third Security, LLC. Issuer counsel was Paul Hastings LLP and investor counsel was Troutman Sanders, LLP. via PlacementTracker.
BioLineRx Limited (BLRX) announced that it has raised $21,000,000 in a CMPO/Overnight transaction. The common stock was sold at $2.50 per share, an approximate 14% discount to the market price ($2.92) of BLRX at deal announcement. Roth Capital Partners acted as Sole Book-Running Manager and Maxim Group LLC acted as Co-Manager on the transaction. Placement Agent counsel was Goodwin Procter, LLP and issuer counsel was Morrison & Foerster and Yigal Arnon & Company. Note this Placement is subject to customary closing conditions and is expected to close by 03/07/2014.
BioTime, Inc. (BTX) announced that it has raised $3,500,000 in a Convertible Preferred Stock transaction. The fixed conversion price of the Convertible Preferred Stock is $4.00 per share, an approximate 8.4% premium to the market price ($3.69) of BTX at deal announcement. via PlacementTracker.
Cormedix Inc. (CRMD) announced that it has raised $7,400,000 in a Registered Direct transaction. The common stock was sold at $2.50 per share, an approximate 13% discount to the market price ($2.89) of CRMD at deal announcement. A series of 1,036,000 66-Month Warrants with an exercise price of $3.10 per share (7.27% premium) was issued to the investors in this transaction. Roth Capital Partners acted as the exclusive agent on the transaction. Issuer counsel was Wyrick Robbins Yates & Ponton and Placement Agent counsel was Lowenstein Sandler.
